Literature DB >> 11869621

Surgery versus radiotherapy for muscle invasive bladder cancer.

M D Shelley1, J Barber, T Wilt, M D Mason.   

Abstract

BACKGROUND: Muscle invasive bladder cancer is a serious clinical problem and is fatal for the majority of patients. Alternative treatments for this condition are radical cystectomy or radical radiotherapy. The choice of treatment varies according to the resident country. The ideal treatment would be a bladder preserving therapy with total eradication of the tumour without compromising survival.
OBJECTIVES: The objective of this review was to compare the overall survival after radical surgery (cystectomy) versus radical radiotherapy in patients with muscle invasive cancer. SEARCH STRATEGY: We searched the Cochrane Controlled Trials Register (July 2001), MEDLINE (July 2001), EMBASE (July 2001), CancerLIT (July 2001), Healthstar (July 2001) and the Database of Abstracts of Reviews of Effectiveness (July 2001). Attempts to contact authors of unpublished data were undertaken. SELECTION CRITERIA: Randomised trials comparing surgery versus radiotherapy were eligible for assessment. DATA COLLECTION AND ANALYSIS: Three reviewers assessed trial quality based on the Cochrane Guidelines. Data were extracted from the text of the article or extrapolated from the Kaplan-Meier plot. The Peto odds ratio was determined to compare the overall survival and disease-specific survival. Analysis was performed on an intention-to-treat basis and treatment actually received. MAIN
RESULTS: Three randomised trials comparing pre-operative radiotherapy followed by radical cystectomy (surgery) versus radical radiotherapy with salvage cystectomy (radical radiotherapy) were eligible for assessment. These trials represented a total of 439 patients, 221 randomised to surgery and 218 to radical radiotherapy. Three trials were combined for the overall survival results and one for the disease-specific analysis [Bloom 1982]. The mean overall survival (intention-to-treat analysis) at 3 and 5 years were 45% and 36% for surgery, and 28% and 20% for radiotherapy, respectively. Peto odds ratio (95% Confidence Interval) analysis consistently favoured surgery in terms of overall survival. The results were significantly in favour of surgery at 3 years (OR = 1.91, 95% CI 1.30 -2.82) and at 5 years (OR = 1.85 95% CI 1.22 - 2.82). On a 'treatment received' basis, the results were significantly in favour of surgery at 3 (OR = 1.84, 95% CI 1.17 - 2.90) and 5 years (OR = 2.17, 95% CI 1.39 - 3.38) for overall survival and at 3 years (OR = 1.96, 95% CI 1.06,3.65) for disease-specific survival. REVIEWER'S
CONCLUSIONS: The analysis of this review suggests that there is an overall survival benefit with radical surgery compared to radical radiotherapy in patients with muscle-invasive bladder cancer. However, it must be considered that only three trials were included for analysis, the patients numbers were small and that many patients did not receive the treatment they were randomised to. It must also be noted that many improvements in both radiotherapy and surgery have taken place since the initiation of these trials.

Entities:  

Mesh:

Year:  2002        PMID: 11869621     DOI: 10.1002/14651858.CD002079

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  8 in total

1.  Bladder preservation for localized muscle-invasive bladder cancer: the survival impact of local utilization rates of definitive radiotherapy.

Authors:  Kevin R Kozak; Maryam Hamidi; Matthew Manning; John S Moody
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-03-06       Impact factor: 7.038

2.  Treatment results of radiation therapy for muscle-invasive bladder cancer.

Authors:  Tanja Langsenlehner; Carmen Döller; Franz Quehenberger; Heidi Stranzl-Lawatsch; Uwe Langsenlehner; Karl Pummer; Karin S Kapp
Journal:  Strahlenther Onkol       Date:  2010-03-26       Impact factor: 3.621

3.  Radiotherapy in muscle-invasive bladder cancer: the latest research progress and clinical application.

Authors:  Shuo Zhang; Yong-Hua Yu; Yong Zhang; Wei Qu; Jia Li
Journal:  Am J Cancer Res       Date:  2015-01-15       Impact factor: 6.166

4.  Concurrent chemoradiotherapy with low dose weekly gemcitabine in medically inoperable muscle-invasive bladder cancer patients.

Authors:  B M Atasoy; F Dane; I Alsan Cetin; Z Ozgen; A Ucuncu Kefeli; R Ibrahimov; N S Turhal; U Abacioglu; L Turkeri
Journal:  Clin Transl Oncol       Date:  2013-04-25       Impact factor: 3.405

5.  Perioperative search for circulating tumor cells in patients undergoing radical cystectomy for bladder cancer.

Authors:  A Karl; S Tritschler; S Hofmann; C G Stief; C Schindlbeck
Journal:  Eur J Med Res       Date:  2009-11-03       Impact factor: 2.175

Review 6.  Bladder-sparing protocols in the treatment of muscle-invasive bladder cancer.

Authors:  Côme Tholomier; Luis Souhami; Wassim Kassouf
Journal:  Transl Androl Urol       Date:  2020-12

7.  Trimodality bladder-sparing approach without neoadjuvant chemotherapy for node-negative localized muscle-invasive urinary bladder cancer resulted in comparable cystectomy-free survival.

Authors:  Cheng-Yen Lee; Kai-Lin Yang; Hui-Ling Ko; Rong-Yau Huang; Pei-Pin Tsai; Ming-Tsun Chen; Yi-Chia Lin; Thomas I-Sheng Hwang; Guang-Dar Juang; Kwan-Hwa Chi
Journal:  Radiat Oncol       Date:  2014-09-24       Impact factor: 3.481

8.  Treating bladder adenocarcinoma.

Authors:  Georgios Tsironis; Aristotle Bamias
Journal:  Transl Androl Urol       Date:  2018-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.